Glucagon-like peptide analogues for type 2 diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2011, Pages

  Shyangdan, Deepson S ^a   Royle, Pamela ^a   Clar, Christine ^b   Sharma, Pawana ^c   Waugh, Norman ^a   Snaith, Ailsa ^d  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b Systematic Reviews   (Germany)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TASPOGLUTIDE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN;

ABDOMINAL DISTENSION; BIOSYNTHESIS; BLOOD PRESSURE REGULATION; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CELL FUNCTION; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG SAFETY; GASTROINTESTINAL DISEASE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HALLUCINATION; HEADACHE; HUMAN; HYPOGLYCEMIA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INSULIN RELEASE; LIFESTYLE MODIFICATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SATIETY; SIDE EFFECT; STOMACH PARESIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; URTICARIA; VOMITING; WEIGHT REDUCTION; BLOOD; META ANALYSIS; METABOLISM;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80155183665     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006423.pub2     Document Type: Review

References (115)

1. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes. Diabetes Care 2009;32(10):1880-6.
2. Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet Aug 2010;376:431-9.
3. Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 2011;96(5):1301-10.
4. Diamant M, Van GL, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43.
5. Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabetic Medicine 2009;26(7):722-8.
6. Best JH, Rubin RR, Zhuang D, Velez F, Kim T, Peyrot M. Higher diabetes treatment satisfaction associated with improved glucose control for both exenatide once weekly and twice daily. Diabetes 2008;57:A520.
7. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.[see comment]. Lancet 2008;372(9645):1240-50.
8. Ratner RE, Rosenstock J, Boka G, DRI6012 Study Investigators. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabetic Medicine 2010;27(9):1024-32.
9. Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obesity and Metabolism 2010;12:341-7.
10. Marre M, Shaw J, Brändle M, Bebakar WMW, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Medicine 2009;26:268-78.
11. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32(1):84-90.
12. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32(7):1224-30.
13. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55.
14. Buse J, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, et al. Switching from twice-daily exenatide to once-daily liraglutide improves glycemic control in T2D on oral agents. American Diabetes Association. 2009:591-P.
15. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).[see comment]. Lancet 2009;374(9683):39-47.
16. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56.
17. Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd, EGO Study Group. The effects of LY2189265, a long-acting glucagon-like peptide-1 analog, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes, Obesity and Metabolism Jan 2011;13:418-25.
18. Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial. Diabetes, Obesity and Metabolism Jan 2011;13(1):81-88.
19. Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009;32(7):1237-43.
20. Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R. Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. Diabetic Medicine 2010;27:556-62.
21. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009 Nov 7;374:1606-16.
22. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clinical Therapeutics 2007;29:2333-48.
23. Secnik K, Hayes C, Matza L, Kim S, Oglesby A, Yurgin N, et al. Improved treatment satisfaction in patients with type-2 diabetes treated with exenatide or insulin glargine. Value in Health 2005;8:A155-A156.
24. Trautmann M, Burger J, Johns D, Brodows R, Okerson T, Roberts A, et al. Less hypoglycemia with exenatide versus insulin glargine, despite similar Hba(1c) improvement, in patients with T2dm adjunctively treated with metformin. Diabetes 2007;56:A45.
25. Trautmann M, Burger J, Johns D, Brodows R, Okerson T, Roberts A, et al. Relationship between hypoglycaemia, background oral antidiabetic agent, and glycaemic control in patients treated with exenatide or insulin glargine. Diabetologia 2007;50:S338.
26. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2006;8:436-47.
27. Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, et al. LEAD-3 Study Group. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obesity and Metabolism 2010 Jul;12(7):604-12.
28. Brixner DI, McAdam-Marx C, Ye X, Boye KS, Nielsen LL, Wintle M, et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obesity and Metabolism 2009 Dec;11(12):1122-30.
29. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-35.
30. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O, Liraglutide Dose-Response Study Group. Effects of liraglutide (NN2211), a long-acting GLP-1analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabetic Medicine 2005;22:1016-23.
31. Gallwitz B, Vaag A, Falahati A, Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. International Journal of Clinical Practice 2010 Jan;64(2):267-76.
32. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.[see comment]. Lancet 2009;373(9662):473-81.
33. Kapitza C, Heise T, Birman P, Jallet K, Ramis J, Balena R. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabetic Medicine 2009 Nov;26(11):1156-64.
34. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93.
35. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR, NN2211-1310 International study group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care 2004;27:1335-42.
36. Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. Clinical Therapeutics 2009 Apr;31(4):806-15.
37. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics 2008;30:1448-60.
38. Harder H, Nielsen L, Thi TDT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004;27:1915-21.
39. Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgraduate Medicine 2009;121(3):5-15.
40. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. American Journal of Hypertension 2010 Mar;23(3):334-39.
41. Riddle MC, Henry RR, Poon TH, Zhang B, Mac MS, John HH, et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes/Metabolism Research and Reviews 2006;22:483-91.
42. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Research and Clinical Practice 2008;81(2):161-8.
43. Trescoli-Serrano C, Rivas M, Fajardo-Montanana C, Del Pino I, Garcia-Zarco M, Martorrell-Barraquet A, et al. Clinical site experience comparing insulin glargine with exenatide treatment in type 2 diabetic patients. Diabetologia 2005;48:A3.
44. Courreges JP, Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabetic Medicine 2008;25(9):1129-31.
45. Horowitz M. Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. Diabetes, Obesity and Metabolism 2008;10:593-02.
46. Valentine WJ, Hammer M, Palmer AJ, Ray JA. Projecting the long-term clinical benefits of treatment with the GLP-1 analogue liraglutide in subjects with type 2 diabetes. Diabetes 2007;56:A568.
47. Vilsboll T, Brock B, Perrild H, Levin K, Lervang HH, Kolendorf K, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabetic Medicine 2008;25(2):152-56.
48. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10.
49. NCT00838903. Efficacy and safety of albiglutide in treatment of type 2 diabetes. http://clinicaltrials.gov/ct2/show/NCT00838903.
50. NCT00838916. A study to determine the safety and efficacy of albiglutide in patients with type 2 diabetes. http://clinicaltrials.gov/ct2/show/NCT00838916.
51. NCT00849017. Safety and efficacy study of albiglutide in type 2 diabetes. http://clinicaltrials.gov/ct2/show/NCT00849017.
52. NCT00849056. Safety and efficacy of albiglutide in type 2 diabetes. http://clinicaltrials.gov/ct2/show/NCT00849056.
53. NCT01098461. Dose ranging study of albiglutide in Japanese subjects. http://clinicaltrials.gov/ct2/show/NCT01098461.
54. NCT01128894. A study to determine the efficacy and safety of albiglutide as compared with liraglutide. http://clinicaltrials.gov/ct2/show/NCT01128894 accessed 17 June 2011.
55. NCT00641056. Efficacy of exenatide once weekly and once-daily insulin glargine in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylurea (DURATION - 3). http://clinicaltrials.gov/ct2/show/NCT00641056.
56. NCT00917267. A study to examine the effects of exenatide once-weekly injection on glucose control and safety in Asian subjects. http://clinicaltrials.gov/ct2/show/NCT00917267.
57. NCT00935532. Study to evaluate the efficacy and safety of exenatide once-weekly injection compared to once-daily insulin in type 2 diabetes mellitus. http://clinicaltrials.gov/ct2/show/NCT00935532.
58. NCT01003184. Efficacy of once-weekly exenatide versus once or twice daily insulin detemir in patients with type 2 diabetes. http://clinicaltrials.gov/ct2/show/NCT01003184.
59. NCT01029886. Safety and efficacy of exenatide once weekly versus liraglutide in subjects with type 2 diabetes. http://clinicaltrials.gov/ct2/show/NCT01029886 accessed 17 June 2011.
60. NCT01144338. Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. http://clinicaltrials.gov/ct2/show/NCT01144338.
61. NCT00856986. The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes. http://clinicaltrials.gov/ct2/show/NCT00856986 accessed 17 June 2011.
62. NCT01117350. Efficacy assessment of insulin glargine versus liraglutide after oral agent failure (EAGLE). http://clinicaltrials.gov/ct2/show/NCT01117350 accessed 17 June 2011.
63. NCT01296412. Comparison of two treatment regimens (sitagliptin versus liraglutide) on participants who failed to achieve good glucose control on metformin alone (MK-0431-403). http://clinicaltrials.gov/ct2/show/NCT01296412 accessed 17 June 2011.
64. NCT01336023. Dual action of liraglutide and insulin degludec in type 2 diabetes: a trial comparing the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in subjects with type 2 diabetes (DUAL™ I). http://clinicaltrials.gov/ct2/show/NCT01336023 accessed 17 June 2011.
65. NCT00707031. GLP-1 agonist AVE0010 versus exenatide in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-X). http://clinicaltrials.gov/ct2/show/NCT00707031 accessed 17 June 2011.
66. NCT00713830. GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of sulfonylurea (GETGOAL-S). http://clinicaltrials.gov/ct2/show/NCT00713830 accessed 17 June 2011.
67. NCT00763815. GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of pioglitazone (GETGOAL-P). http://clinicaltrials.gov/ct2/show/NCT00763815 accessed 17 June 2011.
68. NCT00975286. 24-week treatment with lixisenatide in type 2 diabetes insufficiently controlled with metformin and insulin glargine. http://clinicaltrials.gov/ct2/show/NCT00975286 accessed 17 June 2011.
69. NCT00976937. 24-week study comparing lixisenatide to sitagliptin as add-on to metformin in obese type 2 diabetic patients younger than 50. http://clinicaltrials.gov/ct2/show/NCT00976937 accessed 17 June 2011.
70. NCT00696657. A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide. http://clinicaltrials.gov/ct2/show/NCT00696657 accessed 17 June 2011.
71. NCT00717457. A study of taspoglutide versus exenatide for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both. http://clinicaltrials.gov/ct2/show/NCT00717457 accessed 17 June 2011.
72. NCT00744367. A study of taspoglutide versus placebo for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone. http://clinicaltrials.gov/ct2/show/NCT00744367 accessed 17 June 2011.
73. NCT00754988. A study of taspoglutide versus sitagliptin for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin. http://clinicaltrials.gov/ct2/show/NCT00754988 accessed 17 June 2011.
74. NCT00755287. A study of the safety, tolerability and effect on glycemic control of taspoglutide versus insulin glargine in insulin naive type 2 diabetic patients inadequately controlled with metformin plus sulphonylurea. http://clinicaltrials.gov/ct2/show/NCT00755287 accessed 17 June 2011.
75. NCT00823992. A study of taspoglutide versus placebo for the treatment of obese patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. http://clinicaltrials.gov/ct2/show/NCT00823992 accessed 17 June 2011.
76. NCT00909597. A study of taspoglutide versus pioglitazone in patients with type 2 diabetes. http://clinicaltrials.gov/ct2/show/NCT00909597 accessed 17 June 2011.
77. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002;143(8):3152-61.
78. American Diabetes Association. Report on the Expert Committee on the Diagnosis and Classication of Diabetes Mellitus. Diabetes Care 1997;20(Suppl 1):S5-20.
79. The Expert Committee on the Diagnosis and Classication of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22(Suppl 1):S5-19.
80. Amori RE, Lau J, Pittas, AG. Efficacy and safety of incretin therapy in type 2 diabetes. Journal of the American Medical Association 2007;298(2):194-206.
81. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004;53(9):2492-500.
82. Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clinical Endocrinology 2009;70:343-53.
83. Butler PC, Matveyenko AV, Dry S, Bhushan A, Elashoff R. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?. Diabetologia 2010;53:1-5.
84. Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes, Obesity and Metabolism Jun 2011;13(6):559-66.
85. EMEA. Assessment report for Victoza (liraglutide). http://www.emea.europa.eu/humandocs/PDFs/EPAR/victoza/H-1026-en6.pdf accessed 10 March 2010.
86. Farilla L, Bulotta A, Hirshberg B, Li CS, Khoury N, Noushmehr H, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.[see comment]. Endocrinology 2003;144(12):5149-58.
87. FDA. Information for Healthcare Professionals: Exenatide (marketed as Byetta). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm accessed 10 March 2010.
88. FDA. Byetta (exenatide) prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf accessed 10 March 2010.
89. FDA. Information for Healthcare Professionals: Reports of Altered Kidney Function in patients using Exenatide (Marketed as Byetta). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm188656.htm accessed 10 March 2010.
90. FDA. Byetta Safety Update for Healthcare Professionals. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190406.htm accessed 10 March 2010.
91. Girman CJ, Kou TD, Cai B, Alexander CM, O'Neill EA, Williams-Herman DE, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obesity and Metabolism Sep 2010;12(9):766-71.
92. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
93. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
94. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
95. Journal Watch. FDA Reminds Clinicians of Liraglutide's Risks for Pancreatitis and Cancer. http://firstwatch.jwatch.org/cgi/content/full/2011/614/2?q=topic_diabetes accessed 17 June 2011.
96. Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemiaand no weight change with the once-daily humanglucagon-like peptide-1 analogue liraglutide as add-onto sulphonylurea in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2010;12:341-7.
97. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. The Journal of Biological Chemistry 2003;278(1):471-8.
98. Loh JA, Clement SC. Efficacy of exenatide therapy over 12 months in a "real world" setting. Diabetes 2007;56:A152.
99. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA group. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement. British Medical Journal 2009;339:b2535.
100. Monami M, Marchionni N, Mannucci E. Glucagon like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. European Journal of Endocrinology 2009;160:909-17.
101. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-03.
102. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36(8):741-4.
103. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycaemic clamp experiments in healthy volunteers. The Journal of Clinical Endocrinology and Metabolism 2002;87(3):1239-46.
104. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians 2008; Vol. http://www.nice.org.uk/nicemedia/pdf/CG66FullGuideline0509.pdf.
105. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87 2009; Vol. http://www.nice.org.uk/cg87.
106. National Institute for Health and Clinical Excellence. Liraglutide for the treatment of type 2 diabetes mellitus. NICE technology appraisal guidance 203. http://guidance.nice.org.uk/TA203 2010.
107. Norris SL, Lee N, Thakurta S, Chan BKS. Exenatide efficacy and safety: a systematic review. Diabetic Medicine 2009;26:837-46.
108. Pratley RE. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape Journal of Medicine 2008;10(7):171.
109. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocrine Disorders 2010;10:20.
110. Shyangdan D, Cummins E, Royle P, Waugh N. Liraglutide for the treatment of type 2 diabetes. Health Technology Assessment 2011;15(Suppl. 1):75-84.
111. Turner RC, Holman RR. The UK Prospective Diabetes Study. UK Prospective Diabetes Study Group. Annals of Medicine 1996;28(5):439-44.
112. UKPDS Study Group. UKPDS 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995;44:1249-58.
113. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment July 2010;14(36):1-248.
114. Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-53.
115. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta- cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48(12):2270-6.